newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

  • IGC Pharma announced approximately 80% patient enrollment in its Phase 2 CALMA clinical trial for IGC-AD1 targeting agitation in Alzheimer's disease.
  • The company expects to complete enrollment in mid-2026, which will precede database lock \& top-line results.
  • CEO Ram Mukunda stated the trial has entered its final recruitment phase with strong momentum toward 100% enrollment.
  • As a randomized, double-blind, placebo-controlled study, efficacy outcomes will not be analyzed via interim data to preserve trial integrity.
  • The CALMA trial utilizes a diversified US \& Canadian clinical network to sustain enrollment momentum.
  • Agitation affects up to 76% of Alzheimer's patients, representing a significant unmet need despite a recent first-in-class approval.
  • IGC-AD1 is an investigational therapy being evaluated for safety \& efficacy in patients with Alzheimer's-related agitation.
  • IGC Pharma is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer's \& metabolic disorders.
  • The company's pipeline includes TGR-63 for amyloid plaques and early-stage programs targeting neurodegeneration, tau proteins, \& metabolic dysfunctions.
  • This press release contains forward-looking statements subject to risks regarding enrollment timelines, data readouts, \& regulatory approvals.